



AUROBINDO PHARMA LIMITED

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

PART I STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2012												Rs.in Lakhs	
Particulars	Stand alone						Consolidated						
	Three months ended			Nine months ended			Three months ended			Nine months ended			
	31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012	31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Income from operations													
(a) Net sales/income from operations (Net of excise duty)	141,263	137,248	118,072	389,767	313,245	420,461	155,195	148,105	126,373	423,044	337,981	455,056	
(b) Other operating income	1,874	1,879	2,078	5,450	5,688	7,684	1,814	1,939	2,078	5,450	5,688	7,684	
Total income from operations (net)	143,137	139,127	120,150	395,217	318,933	428,145	157,009	150,044	128,451	428,494	343,669	462,740	
2 Expenses													
(a) Cost of material consumed	85,423	80,547	62,391	232,142	175,009	239,329	78,428	75,052	55,742	210,315	160,350	222,551	
(b) Purchase of stock-in-trade	2,229	1,502	1,149	6,138	1,592	3,552	9,052	11,995	11,177	34,704	21,276	30,030	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8,873)	(2,684)	5,205	(17,505)	8,497	8,987	(9,260)	(11,396)	3,629	(26,410)	6,192	(605)	
(d) Employee benefits expense	10,995	10,809	9,377	32,016	27,284	36,410	16,682	16,703	14,076	48,812	39,661	53,568	
(e) Depreciation and amortisation expense	4,224	4,213	3,601	12,541	10,456	14,294	6,079	5,983	5,521	17,946	14,660	20,053	
(f) Provision for decline in the value of long-term investment	-	1,800	-	1,800	-	2,687	-	-	-	-	-	-	
(g) Other expenses	25,113	23,431	20,470	70,118	57,418	77,681	36,197	32,662	24,711	96,160	69,218	96,183	
Total expenses	119,111	119,618	102,193	337,250	280,256	382,940	137,178	130,999	114,856	381,527	311,357	421,780	
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	24,026	19,509	17,957	57,967	38,677	45,205	19,831	19,045	13,595	46,967	32,312	40,960	
4 Other Income	108	622	211	838	1,076	1,906	564	659	523	1,445	1,878	2,470	
5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	24,134	20,131	18,168	58,805	39,753	47,111	20,395	19,704	14,118	48,412	34,190	43,430	
6 Finance costs (refer note 7)	2,850	2,999	2,494	8,879	6,061	9,311	3,312	3,350	2,764	9,973	6,755	10,278	
7 Foreign exchange (Gain)/Loss (refer note 7)	6,496	(12,485)	14,638	13,336	29,208	19,596	7,336	(11,767)	14,450	16,214	32,674	22,330	
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	14,788	29,617	1,036	36,590	4,484	18,204	9,747	28,121	(3,096)	22,225	(5,239)	10,822	
9 Exceptional item	-	-	-	-	31,986	31,986	1	12	-	13	31,986	32,118	
10 Profit/(Loss) from ordinary activities before tax (8-9)	14,788	29,617	1,036	36,590	(27,502)	(13,782)	9,746	28,109	(3,096)	22,212	(37,225)	(21,296)	
11 Tax expense/(credit)	360	5,816	(257)	3,345	(14,449)	(9,521)	646	5,913	(239)	3,819	(14,070)	(8,881)	
12 Net Profit/(Loss) for the period (10-11)	14,428	23,801	1,293	33,245	(13,053)	(4,261)	9,100	22,196	(2,857)	18,393	(23,155)	(12,415)	
13 Minority Interest							(81)	(39)	(3)	(132)	(5)	(64)	
14 Net Profit/(Loss) after taxes and minority interest (12-13)	14,428	23,801	1,293	33,245	(13,053)	(4,261)	9,181	22,235	(2,854)	18,525	(23,150)	(12,351)	
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,911	2,911	2,911	2,911	2,911	2,911							
16 Reserves excluding Revaluation Reserve						246,406							
17 Earnings per share of Re.1/- each (not annualised)													
(a) Basic	4.96	8.17	0.44	11.42	(4.48)	(1.46)	3.15	7.64	(0.98)	6.36	(7.95)	(4.24)	
(b) Diluted	4.96	8.17	0.44	11.42	(4.48)	(1.46)	3.15	7.64	(0.98)	6.36	(7.95)	(4.24)	

**AUROBINDO PHARMA LIMITED**

Regd.Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

PART II							
SELECT INFORMATION FOR THE QUARTER & NINE MONTHS ENDED 31.12.2012							
	Particulars	Three months ended			Nine months ended		Year Ended
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	131,708,307	131,708,307	131,794,307	131,708,307	131,794,307	131,708,307
	- Percentage of Shareholding	45.24	45.24	45.27	45.24	45.27	45.24
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	- Number of Shares	35,932,297	34,300,902	32,718,605	35,932,297	32,718,605	35,523,605
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	22.54	21.52	20.54	22.54	20.54	22.28
	- Percentage of Shares (as a % of the total share capital of the company)	12.34	11.78	11.24	12.34	11.24	12.20
b)	Non-encumbered						
	- Number of Shares	123,480,686	125,112,081	126,608,378	123,480,686	126,608,378	123,889,378
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	77.46	78.48	79.46	77.46	79.46	77.72
	- Percentage of Shares (as a % of the total share capital of the company)	42.42	42.98	43.49	42.42	43.49	42.56

	Particulars	Three months ended 31.12.2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	51
	Disposed of during the quarter	50
	Remaining unresolved at the end of the quarter	1

NOTES:

- The above unaudited financial results as reviewed by the Audit Committee has been approved by the Board at its meeting held on February 07, 2013. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Income from operations of standalone for the current quarter includes exports of Rs.102,921 lakhs (Quarter ended December 31, 2011: Rs.88,511 lakhs).
- Net sales for the current quarter include dossier income in standalone of Rs.1,857 lakhs (Quarter ended December 31, 2011:Rs.2,064 lakhs) and in consolidated of Rs.3,855 lakhs (Quarter ended December 31, 2011 : Rs.2,276 lakhs).
- Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.4,999 lakhs, Rs.4,669 lakhs , Rs.4,586 lakhs for three months ended Dec 31, 2012, Sep 30, 2012 and Dec 31, 2011 respectively and Rs.14,444 lakhs, Rs.12,658 lakhs for the nine months ended Dec 31,2012 and Dec 31, 2011 respectively and Rs.17,447 lakhs for the year ended March 31, 2012 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- The results for the quarter in this statement have been reported in format recommended as per the SEBI circular dated April 16, 2012. Accordingly all other periods have also been restated to conform with the current period presentation.
- The Board has approved an interim dividend @100% i.e. Re1/-(Rupee One only) per equity share of Re1/-(Rupee One only) for the year 2012-13.

By Order of the Board

Place: Hyderabad
Date : February 7, 2013

www.aurobindo.com

N.Govindarajan
Managing Director